Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis

Journal of Managed Care Pharmacy
doi 10.18553/jmcp.2006.12.7.555
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Academy of Managed Care Pharmacy


Related search